Stock Analysis of Pharvaris BV (PHVS) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code PHVS
Close 18.96
Change 0.060 / 0.317 %
Volume 9427.00
Vol Change -9964.00 / 51.38 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Pharvaris BV
PE (TTM)

-9.72

Very Poor
Price / Book

3.88

Very Poor
Price / Sales

0

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

1020.36 M

Enterprise Value

629005 K

ROA (TTM)

-37.79

Very Poor
ROE (TTM)

-39.91

Very Poor
Net Margin (TTM)

0

Poor
Revenue

%

0
Net Profit

40.60 %

-107324.07 K
Debt to Equity

0.0005

Excellent
Altman Z Score

41.10

Excellent
Quick Ratio

27.25

Excellent
Cash Ratio

26.79

Excellent


Highs/Lows of Pharvaris BV
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week20.18 6.05 % 0.513 % 20.5718.81528-May-2431-May-24
Two Week20.35 6.83 % 0.486 % 21.869718.81524-May-2431-May-24
One Month24.59 22.90 % 4.80 % 25.518.81502-May-2431-May-24
Three Month22.94 17.35 % 3.56 % 27.46417.5708-Mar-2422-Apr-24
Six Months17.21 10.17 % 15.54 % 33.016.8106-Feb-2401-Dec-23
One year8.6 120.47 % 26.26 % 33.08.206-Feb-2407-Jun-23
Two year17.994 5.37 % 27.72 % 33.01.7706-Feb-2402-Dec-22


Technical View of Pharvaris BV
RSI

37.12

Neutral
MACD

-0.829

Bearish
ADX

7.45

Neutral
Super Trend

17.77

Mild Bullish
Williams %R

-97.26

Mild Bullish
CCI

-125.92

Mild Bearish


EMA 5

19.33

Mild Bearish
EMA 15

20.20

Strong Bearish
EMA 50

21.77

Strong Bearish
EMA 100

22.48

Strong Bearish
SMA 100

24.37

Strong Bearish
SMA 200

22.40

Mild Bearish
SMA 5 / 20

19.42 / 20.74

Mild Bearish
SMA 15 / 50

20.36 / 21.69

Strong Bearish
SMA 50 / 200

21.69 / 22.40

Strong Bearish




Charts of Pharvaris BV


Returns of Pharvaris BV with Peers
Period / StockPHVSMDRXARCTSTVN
1 Week-6.05%25.61%27.62%1.75%
1 Mth-22.90%22.15%51.78%-27.53%
3 Mth-17.35%62.94%0.129%-38.70%
6mth10.17%-14.98%62.11%-23.00%
1 Year120.47%-18.46%41.95%-24.49%
2 Year5.37%-42.25%95.22%25.82%
5 Years--3.37%456.02%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Pharvaris BV with Peers
Ratio / StockPHVSMDRXARCTSTVN
PE-9.72-47.18-9.9539.91
P/B3.880.9963.604.18
ROA-37.79-1.34-23.596.92
ROE-39.91-2.11-36.1611.97
Debt To Equity0.0005000.340
Revenue0
% 		0
100.00 % 		292719 K
42.10 % 		1056.81 M
7.43 %
Net Income-107324.07 K
40.60 % 		0
100.00 % 		99329.00 K
962.46 % 		148780 K
4.15 %


Technicals of Pharvaris BV with Peers
Technical / StockPHVSMDRXARCTSTVN-
ADX7.4534.6237.5130.15
CMF-0.277-0.01770.054-0.273
MFI34.874.7874.8938.80
RSI37.1264.3169.0036.78
MACD Abv SignalFalseTrueTrueTrue
Price Above 50 MAFalseTrueTrueFalse-
Price Above 200 MAFalseFalseTrueFalse-


About : Pharvaris BV

Address : Emmy Noetherweg 2, Leiden, Netherlands, 2333 CH
Tel : 31 71 203 6410
URL : https://pharvaris.com
Code : PHVS, ISIN : NL00150005Y4, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 05_Feb_2021
Employee Count : 83

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.


Note : All Data Generated at the End of Trading Hours (EOD Data)